Literature DB >> 7982660

Ursodeoxycholate protects oxidative mitochondrial metabolism from bile acid toxicity: dose-response study in isolated rat liver mitochondria.

S Krähenbühl1, S Fischer, C Talos, J Reichen.   

Abstract

The effect of ursodeoxycholate and tauroursodeoxycholate on the toxicity of lipophilic bile acids (chenodeoxycholate and lithocholate) on the function of the electron transport chain was investigated in isolated rat liver mitochondria. At a concentration of 30 mumol/L, both chenodeoxycholate and lithocholate reduced state 3 oxidation rates and respiratory control ratios of L-glutamate, succinate and duroquinol. In contrast, ADP/O ratios of these substrates and oxidative metabolism of ascorbate were not significantly affected. Ursodeoxycholate did not impair mitochondrial oxidative metabolism up to concentrations of 100 mumol/L; at 300 mumol/L, however, it decreased state 3 oxidation rates and respiratory control ratios of L-glutamate, succinate and duroquinol. Tauroursodeoxycholate had no significant inhibitory effect on state 3 oxidation rates of L-glutamate and succinate at concentrations up to 300 mumol/L. When ursodeoxycholate (final concentration, 30 mumol/L or 100 mumol/L) was added to mitochondrial incubations containing chenodeoxycholate or lithocholate, the toxic effects of lipophilic bile acids on mitochondrial oxidative metabolism were partially reversed. However, 300 mumol/L ursodeoxycholate, in combination with chenodeoxycholate or lithocholate, exhibited greater toxicity compared with incubations containing only the individual bile acids. In contrast to ursodeoxycholate, tauroursodeoxycholate did not reduce the toxic effects of chenodeoxycholate or lithocholate on mitochondrial metabolism. Ursodeoxycholate (100 mumol/L) significantly decreased the incorporation of chenodeoxycholate into mitochondrial membranes, whereas the decrease in lithocholate incorporation was not statistically significant. These studies demonstrate that ursodeoxycholate, but not tauroursodeoxycholate, decreases the toxicity of lipophilic bile acids on the function of the electron but increases bile acid-induced mitochondrial toxicity at higher concentrations.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7982660     DOI: 10.1002/hep.1840200632

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  15 in total

1.  Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment.

Authors:  M Leuschner; C F Dietrich; T You; C Seidl; J Raedle; G Herrmann; H Ackermann; U Leuschner
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

Review 2.  Clinical pharmacokinetics of therapeutic bile acids.

Authors:  A Crosignani; K D Setchell; P Invernizzi; A Larghi; C M Rodrigues; M Podda
Journal:  Clin Pharmacokinet       Date:  1996-05       Impact factor: 6.447

3.  Mitochondrial genome depletion dysregulates bile acid- and paracetamol-induced expression of the transporters Mdr1, Mrp1 and Mrp4 in liver cells.

Authors:  M J Perez; E Gonzalez-Sanchez; A Gonzalez-Loyola; J M Gonzalez-Buitrago; J J G Marin
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

4.  Ursodeoxycholic acid suppresses extent of lipid peroxidation in diseased liver in experimental cholestatic liver disease.

Authors:  P Ljubuncic; Z Tanne; A Bomzon
Journal:  Dig Dis Sci       Date:  2000-10       Impact factor: 3.199

5.  Effect of deoxycholic acid and ursodeoxycholic acid on lipid peroxidation in cultured macrophages.

Authors:  P Ljubuncic; B Fuhrman; J Oiknine; M Aviram; A Bomzon
Journal:  Gut       Date:  1996-09       Impact factor: 23.059

6.  Ursodeoxycholic acid ameliorates experimental ileitis counteracting intestinal barrier dysfunction and oxidative stress.

Authors:  Carlos Felipe Bernardes-Silva; Adérson O M C Damião; Aytan M Sipahi; Francisco R M Laurindo; Kiyoshi Iriya; Fabio P Lopasso; Carlos A Buchpiguel; Maria Laura L Lordello; Carmem L O Agostinho; Antonio A Laudanna
Journal:  Dig Dis Sci       Date:  2004-10       Impact factor: 3.199

7.  Hepatoprotection with tauroursodeoxycholate and beta muricholate against taurolithocholate induced cholestasis: involvement of signal transduction pathways.

Authors:  P Milkiewicz; M G Roma; E Elias; R Coleman
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

Review 8.  Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?

Authors:  Agostino Di Ciaula; Salvatore Passarella; Harshitha Shanmugam; Marica Noviello; Leonilde Bonfrate; David Q-H Wang; Piero Portincasa
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

Review 9.  Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD).

Authors:  Ignazio Grattagliano; Agostino Di Ciaula; Jacek Baj; Emilio Molina-Molina; Harshitha Shanmugam; Gabriella Garruti; David Q-H Wang; Piero Portincasa
Journal:  Methods Mol Biol       Date:  2021

10.  Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors.

Authors:  Edana Cassol; Vikas Misra; Alexander Holman; Anupa Kamat; Susan Morgello; Dana Gabuzda
Journal:  BMC Infect Dis       Date:  2013-05-04       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.